ORMP
ORAMED PHARMACEUTICALS INC
$2.15
Earnings Summary
Revenue | $0Mn |
Net Profits | $0.01Mn |
Net Profit Margins | 1035.19% |
Highlights
ORAMED PHARMACEUTICALS INC’s revenue fell -99.9% since last year same period to $0Mn in the Q3 2022. On a quarterly growth basis, ORAMED PHARMACEUTICALS INC has generated -99.9% fall in its revenue since last 3-months.
ORAMED PHARMACEUTICALS INC’s net profit jumped 100.1% since last year same period to $0.01Mn in the Q3 2022. On a quarterly growth basis, ORAMED PHARMACEUTICALS INC has generated 100.07% jump in its net profits since last 3-months.
ORAMED PHARMACEUTICALS INC’s net profit margin jumped 203.17% since last year same period to 1035.19% in the Q3 2022. On a quarterly growth basis, ORAMED PHARMACEUTICALS INC has generated 166.24% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the ORAMED PHARMACEUTICALS INC post its latest quarter earnings
EPS Estimate Current Quarter | -0.24 |
EPS Estimate Current Year | -0.24 |
Highlights
ORAMED PHARMACEUTICALS INC’s earning per share (EPS) estimates for the current quarter stand at -0.24 - a -23.28% fall from last quarter’s estimates.
ORAMED PHARMACEUTICALS INC’s earning per share (EPS) estimates for the current year stand at -0.24.
Key Ratios
Key ratios of the ORAMED PHARMACEUTICALS INC post its Q1 2023 earnings
Earning Per Share (EPS) | 0 |
Return on Assets (ROA) | -0.15 |
Return on Equity (ROE) | -0.24 |
Highlights
ORAMED PHARMACEUTICALS INC’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q1 2023. This indicates that the ORAMED PHARMACEUTICALS INC has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. ORAMED PHARMACEUTICALS INC’s return on assets (ROA) stands at -0.15.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. ORAMED PHARMACEUTICALS INC’s return on equity (ROE) stands at -0.24.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2021-07-14 | -0.2 | -0.17 | 15% |
2022-01-11 | -0.16 | -0.22 | -37.5% |
2021-04-13 | -0.17 | -0.17 | 0% |
2021-11-24 | -0.18 | -0.21 | -16.67% |
Company Information
Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which has the potential to be the first commercial oral insulin capsulefor the treatment of diabetes. The Company has completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule, ORMD-0901.
Organisation | ORAMED PHARMACEUTICALS INC |
Headquarters | 1185 Avenue of the Americas, New York, NY, United States, 10036 |
Employees | 0 |
Industry | Health Technology |
CEO | Nadav Kidron |
